PCN259 SHOULD HEALTH STATE UTILITY VALUES (HSUVS) IN CANCER IMMUNOTHERAPIES (IOS) BE ANALYZED BY TIME TO DEATH (TTD) OR PROGRESSION STATUS? RESULTS OF A SIMULATION STUDY
Abstract
Authors
A.J. Hatswell A. Bullement M. Schlichting M. Bharmal